HCC incidence and recurrence after DAAs: new insights

作     者：Necati Örmeci Necati ?rmeci

作者机构：Department of GastroenterologyAnkara University Medical SchoolAnkara 06590Turkey 

出 版 物：《Hepatoma Research》 (肝癌研究（英文版）)

年 卷 期：2019年第5卷第4期

页      面：9-15页

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

主　　题：infection hepatic cirrhosis 

摘      要：Hepatit C virus(HCV)infection is a global health and economic problem in the *** is the cause of chronic active hepatitis,liver cirrhosis,hepatic decompensation,hepatocellular carcinoma(HCC)and extrahepatic *** 2013,standard care of HCV infection was the combination of Pegylated Interferon(PEG IFN)and *** Virologic Response(SVR)rate of this combination was approximately 50%after 48 weeks of *** fifth of patients who had this combination had to stop treatment because of severe side *** of Telaprevir or Boceprevir(first generation of protease inhibitors)to PEG IFN and Ribavirin therapy for 24 or 48 weeks result in a SVR rate around 70%.However,because of severe adverse events,these combinations are not recommended.